Discuss GLOW on glp1chat
Join the forum to discuss research with other members.
At a glance
GLOW combines GHK-Cu, BPC-157 and a TB-500 preparation. The blend targets three visible parts of repair: skin wounds closing, damaged tissue regaining strength, and inflammation around an injury settling down. Here is what each ingredient has actually done in research.
GHK-Cu: A topical gel containing GHK-Cu helped diabetic foot ulcers shrink faster in a controlled study: the median closure of plantar ulcers was 98.5%, versus 60.8% with the inactive gel. In cell studies, GHK-Cu also increased collagen and other material that helps rebuild skin. The human wound result came from a gel applied to the skin.
TB-500: Studies of full-length thymosin beta-4 found that skin-repair cells moved into wounds and new small blood vessels formed. A topical human study of venous ulcers also found faster wound closure at one tested concentration. TB-500 can instead refer to a shorter fragment, which is not the same tested molecule.
BPC-157: In rats with cut Achilles tendons, treated tendons developed better-organized collagen, smaller defects and greater resistance to pulling force. Other rat tendon experiments found fewer inflammatory cells and more new blood vessels around the injury. Laboratory tests also found that tendon cells moved and survived better under stress.
Together: GLOW is intended to combine faster wound closure, stronger repaired tissue and less inflammation around the injury. These results come from studies of the separate ingredients; the exact three-peptide mixture has not been shown to deliver them.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Here is what the research actually measured for GLOW's individual ingredients:
- Skin wounds closed further: In a controlled study of diabetic foot ulcers, a topical GHK-Cu gel produced 98.5% median closure of plantar-ulcer area, compared with 60.8% for the inactive gel. This result belongs to the topical gel and its wound-care setting, not to an injected blend. Read the study.
- Injured tendons became stronger in rats: After an Achilles tendon was cut, BPC-157-treated rats had smaller defects, better-organized collagen and greater resistance to pulling force than controls. Separate laboratory work found that tendon cells moved into the repair area more readily and survived stress better. These are rat and cell outcomes, not a measured human recovery time. Rat study · Cell study.
- Repair cells moved and wounds closed faster in thymosin beta-4 research: Full-length thymosin beta-4 supports cell migration and new small-vessel growth. A topical trial in people with venous ulcers reported a faster-healing signal at one tested concentration. That trial did not test the shorter fragment sometimes called TB-500 or the GLOW mixture. Read the trial.
- Inflammation decreased around injured rat tendons: In a BPC-157 experiment, treated rats had fewer inflammatory cells and lower myeloperoxidase activity, while a measure of new blood-vessel growth increased. The study did not measure pain relief in people or a reduction in swelling after GLOW. Read the rat study.
What this means for GLOW: The mixture is intended to combine wound closure, structural repair and cell movement. No cited study shows that the complete GLOW blend shortens recovery time, reduces pain or scarring, or makes repaired tissue stronger than the individual preparations.
Side effects & evidence limitations
- At the injection site: Redness, itching, tenderness or swelling can occur with an injected preparation. The rate of these reactions has not been measured for the GLOW mixture.
- Possible immune reaction: The FDA flags injected GHK-Cu, BPC-157 and the TB-500 fragment for potential immune reactions associated with peptide aggregation or impurities. The composition and handling of an injectable preparation therefore matter. FDA safety information.
- Reports involving BPC-157: FDA adverse-event reports include injection-site reactions, shortness of breath and darkening of skin or gums. These reports do not establish that BPC-157 caused those events or that they occur with GLOW. FDA review.
Important evidence gap: There is no established adverse-effect rate or long-term safety profile for this exact three-peptide blend. Safety results for topical full-length thymosin beta-4 cannot be used as the safety profile of injected TB-500.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 70 mg · 1 source tables
Standard Approach (3 mL = 23.3 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2,330 mcg | 10 units (0.10 mL) |
Frequency: Inject once daily subcutaneously. This schedule maintains a consistent dose throughout the 4-week cycle, delivering approximately 1.7 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157 per injection. This once-daily regimen aligns with common research protocols for BPC-157 and similar repair peptides[4][5]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily regenerative blend regimen.
- Goal: Support comprehensive tissue healing through synergistic peptide mechanisms—collagen synthesis (GHK-Cu), cell migration and angiogenesis (TB-500), and localized repair with anti-inflammatory effects (BPC-157)[1][3][4].
- Schedule: Daily subcutaneous injections for 4 weeks at a consistent dose, followed by a 2–4 week rest period to assess progress before considering another cycle.
- Dose: 2,330 mcg (2.33 mg) total blend daily, providing approximately 1.7 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157 per injection.
- Reconstitution: 3.0 mL per 70 mg vial (23.3 mg/mL) for precise unit measurements.
- Storage: Lyophilized vials frozen; reconstituted solutions refrigerated; use within 4 weeks.
Straightforward daily dosing approach for balanced peptide delivery.
- Daily Dose: 2,330 mcg (10 units / 0.10 mL) maintained throughout the 4-week cycle.
- Frequency: Once per day (subcutaneous), at a consistent time preferred.
- Cycle Length: 4 weeks of daily dosing, followed by 2–4 weeks off to evaluate progress and allow receptor resetting.
- Volume: Per-injection volume (~0.1 mL) is well below the 1.0–1.5 mL comfort threshold for subcutaneous administration[7].
- Syringe Recommendation: Use 0.3 mL (30-unit) insulin syringes for greater measurement precision at low volumes.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to minimize foaming.
- Gently swirl or roll the vial until fully dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 4 weeks for optimal potency and safety.
Storage Instructions
Proper storage preserves peptide stability and potency.
- Lyophilized: Store at −20 °C (−4 °F) or below for long-term stability (months to over a year)[6]. If freezer unavailable, refrigeration at 2–8 °C (35.6–46.4 °F) is acceptable for shorter durations (weeks). Store in sealed container with desiccant if possible to prevent moisture absorption.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) at all times when not in use[6]. Do not freeze reconstituted solution. Use within 4 weeks (28 days) for optimal potency and safety[6]. Discard any unused solution after this period.
- Allow frozen vials to reach room temperature before opening to prevent condensation.
- Protect reconstituted solution from light (store in amber vial or wrap in foil).
- Inspect solution before each use; discard if discolored, cloudy, or contains precipitate.
Injection Technique
Subcutaneous injection guidance based on clinical best practices[7][7].
- Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry completely.
- Using an insulin syringe (typically 29–31 gauge, 5/16 to 1/2 inch needle), draw up the calculated dose (10 units = 0.1 mL).
- Select a site with adequate subcutaneous tissue (common sites include lower abdomen, thigh, or upper arm).
- Pinch a fold of skin; insert the needle at approximately a 45° angle into the fatty subcutaneous tissue[7]. With short insulin needles, a 90° angle can also be used if injecting into a pinched skin fold.
- Inject slowly over 2–3 seconds; do not aspirate for subcutaneous injections.
- Withdraw needle and apply gentle pressure with a clean cotton swab; do not rub the injection site.
- Rotate sites systematically with each injection, maintaining at least 1–2 inches spacing between sites to prevent tissue irritation.
- Dispose of used syringes and needles immediately in a proper sharps container; never reuse needles.
Materials & quantity planning
Source materials checklist · 70 mg
Plan based on a 4-week daily protocol at standard dosing.
- Peptide Vials (GLOW Blend, 70 mg each):
- 4 weeks (28 days): 1 vial
- Insulin Syringes (U-100, preferably 0.3 mL / 30-unit for precision):
- 4 weeks: 28 syringes (1 per day)
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 4 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- 4 weeks: 56 swabs (2 per day) → recommend 1 × 100-count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 70 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
Vitamins & Hormones (PubMed) — Thymosin β4 Promotes Dermal Healing (2016) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
HSS Journal (PMC) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025) (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Continue exploring
Related topics are not interchangeable compounds or formulations.